related documents
- 1464P The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the international metastatic RCC database consortium (IMDC) Conferences
- 1665P Genomic mutational landscape of solid tumors: Preliminary results from ROME trial Conferences
- 1748P 4-factor model to predict response and survival benefit with durvalumab (D) in previously treated metastatic urinary tract carcinoma (mUTC) Conferences
- 316P First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study Conferences
- 521P Deciphering a three-miRNA signature as a prognostic biomarker in glioma patients: Correlation with DFS and OS Conferences
- 780TiP A phase I dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB Antibody) alone and in combination with pembrolizumab in patients with advanced malignancies Conferences
- CN76 Cost effectiveness of high versus low-to-moderate intensity exercise during oncological treatment: The Phys-Can RCT Conferences